R. Chappell. Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (8):
2127-9(April 2012)6822<m:linebreak></m:linebreak>CI: (c)2012; JID: 9502500; CON: Clin Cancer Res. 2012 Apr 15;18(8):2301-8. PMID: 22282466; 2012/03/16 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
L. Chen, M. Yen, H. Wu, C. Liao, D. Liou, H. Kuo, and T. Chen. Journal of evaluation in clinical practice, 11 (2):
181-93(April 2005)3816<m:linebreak></m:linebreak>Anàlisi de supervivència; SAS.
Y. Chen, C. Hu, and Y. Wang. Biostatistics (Oxford, England), 7 (4):
515-29(October 2006)5077<m:linebreak></m:linebreak>JID: 100897327; 2006/02/14 aheadofprint; ppublish;<m:linebreak></m:linebreak>Risc atribuïble.
B. George, S. Seals, and I. Aban. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology, 21 (4):
686-94(August 2014)Anàlisi de supervivència; Introductori; SAS.
H. Kim. Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (2 Pt 1):
559-65(January 2007)4698<m:linebreak></m:linebreak>LR: 20071203; GR: AI 029530/AI/NIAID NIH HHS/United States; GR: HL 070149/HL/NHLBI NIH HHS/United States; JID: 9502500; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
S. Lagakos. The New England journal of medicine, 355 (2):
113-7(July 2006)4860<m:linebreak></m:linebreak>LR: 20071115; JID: 0255562; 0 (Cyclooxygenase 2 Inhibitors); 0 (Lactones); 0 (Sulfones); 0 (rofecoxib); CON: N Engl J Med. 2005 Mar 17;352(11):1092-102. PMID: 15713943; 2006/06/26 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.